Merus NV Sees Significant Share Increase
Shares of Merus NV (NASDAQ: MRUS) experienced a notable jump in pre-market trading, soaring sharply by 38.2% to reach $95.21. This surge follows an exciting acquisition announcement that caught investors' attention.
Acquisition by Genmab
Genmab has unveiled plans to acquire Merus for an impressive $8 billion in an all-cash deal. This strategic acquisition adds the breakthrough therapy Petosemtamab to Genmab’s late-stage pipeline, further enhancing its portfolio in the competitive biotech landscape.
Pre-Market Trading Highlights
Merus isn’t the only stock making waves in the pre-market session. Let’s take a look at other notable movers in the market.
Top Gainers
- Steakholder Foods Ltd – ADR (NASDAQ: STKH) rose an impressive 92% to $8.32 following the announcement of its acquisition of Twine Solutions.
- JFB Construction Holdings (NASDAQ: JFB) surged 77.4% to $12.15 after revealing a $44 million private placement.
- Plus Therapeutics Inc (NASDAQ: PSTV) gained 24.3% to $0.77 after a national coverage agreement with UnitedHealthcare for its CNSide assay.
- Avalo Therapeutics Inc (NASDAQ: AVTX) increased by 24.1% to $13.40 after a drop of 6% on the previous day.
- Enanta Pharmaceuticals Inc (NASDAQ: ENTA) climbed 22.7% to $9.69, anticipating the release of results from its Phase 2b study of Zelicapavir.
- Canopy Growth Corp (NASDAQ: CGC) saw a rise of 19.4% to $1.60.
- Zura Bio Ltd (NASDAQ: ZURA) rose 18.3% to $2.85, continuing its positive momentum.
- Tilray Brands Inc (NASDAQ: TLRY) surged 17.4% to $1.35, gearing up to announce its first-quarter financial results.
- Larimar Therapeutics Inc (NASDAQ: LRMR) jumped 16.4% to $5.93 as it prepares to update stakeholders on its Nomlabofusp program.
Top Losers
- MoonLake Immunotherapeutics (NASDAQ: MLTX) saw a drastic decline of 86.3% to $8.50, despite positive trial results from the VELA trials.
- Maris Tech Ltd (NASDAQ: MTEK) fell 37.3% to $2.62 after reporting a significant loss of 30 cents per share.
- Sunrise New Energy Co Ltd (NASDAQ: EPOW) dropped 28.1% to $0.88 despite a brief upturn prior to the announcement of a new U.S. lithium battery project.
- Cycurion Inc (NASDAQ: CYCU) declined 15.5% to $0.28 after a steep fall of over 30% the day before.
- bioAffinity Technologies Inc (NASDAQ: BIAF) dipped 14.4% to $4.53 despite previously posting a significant rise after new case studies were released.
- Youxin Technology Ltd (NASDAQ: YAAS) fell 13.9% to $0.058 amid news of a reverse stock split aimed at regaining Nasdaq compliance.
- Top KingWin Ltd (NASDAQ: WAI) decreased by 12.8% to $4.07 after a significant spike earlier due to a sales contract announcement.
- Cellectis SA (NASDAQ: CLLS) saw a decline of 10.4% to $3.01.
- Quantum-Si Inc (NASDAQ: QSI) experienced a drop of 10.1% to $1.34 following the filing for a mixed shelf of up to $300 million.
- Penguin Solutions Inc (NASDAQ: PENG) fell 8.4% to $24.00.
Conclusion
The acquisition of Merus NV by Genmab certainly brings excitement and significant activity within the market. As investors track these developments, staying informed on stock movements can lead to better decision-making.
Frequently Asked Questions
What is the reason for Merus NV's recent share surge?
Merus NV experienced a 38.2% increase in shares after Genmab announced plans to acquire it for $8 billion.
How did Genmab's acquisition impact its stock?
While the focus is on Merus, Genmab's stock movements remain to be seen as the acquisition progresses.
Which stocks reported significant gains?
Significant gainers include Steakholder Foods, JFB Construction Holdings, and Plus Therapeutics.
What were the top losers in pre-market trading?
The most notable decline was in MoonLake Immunotherapeutics, which dropped 86.3% due to recent trial results.
How does this news affect investors?
Investors are advised to monitor these market changes closely, as they can signify new opportunities or potential challenges.
